Valeant Canada has completed the acquisition of Valeo Pharma's dermatology product portfolio and several specialty products.
Valeo Pharma's portfolio includes brands such as Aristocort C and Valisone G.
These treatments add to Valeant Canada's existing line of dermatitis solutions, joining Elidel, Dermatop, Topicort, UltraVate and CeraVe.
The acquisition also includes Veralac for nail dystrophy, which complements Valeant Canada's recently launched topical solution, Jublia, for onychomycosis.
aleo Pharma's portfolio also comprises the specialty products Vancomycin, an injectable antibiotic for severe staphylococcal infections, and Cophylac, a well-known antitussive.
The acquisition of this complementary portfolio of products supports Valeant Canada's desire to build on its current product offering and to meet physician and patient needs.
The company has resumed its skincare buying spree, picking up a dermatology portfolio and an array of specialty products from Valeo Pharma for $25.3 million.
According to Quebec-based Manitex Capital, which owns 40% of subsidiary Valeo, Valeant will fork over $18.3 million in cash and shell out the balance over the next three years, The Canadian Press reports. The new purchase will join a long line of recent dermatology buys, including Solta Medical, Medicis and Obagi Medical.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Valeant Pharmaceuticals
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity